U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Showing 1 - 10 of 16 results

Status:
US Approved Rx (2024)
First approved in 2018

Class (Stereo):
CHEMICAL (ABSOLUTE)



BMN-673 (8R,9S) is the (8R,9S) enantiomer of BMN-673, known as talazoparib. BMN 673 is a novel inhibitor of nuclear enzyme poly (ADP-ribose) polymerase (PARP) with potential antineoplastic activity.
Status:
US Approved Rx (2023)
First approved in 2017

Class (Stereo):
CHEMICAL (ABSOLUTE)



Niraparib (MK-4827) displays excellent PARP 1 and 2 inhibition. Inhibition of PARP in the context of defects in other DNA repair mechanisms provide a tumor specific way to kill cancer cells. Niraparib is in development with TESARO, under licence fro...
Status:
US Approved Rx (2017)
First approved in 2014

Class (Stereo):
CHEMICAL (ACHIRAL)



Olaparib is an oral inhibitor of poly (ADP-ribose) polymerase enzymes, including PARP1, PARP2, and PARP3 which are involved in normal cellular homeostasis, such as DNA transcription, cell cycle regulation, and DNA repair. Olaparib has shown activity ...
Status:
Investigational

Class (Stereo):
CHEMICAL (ABSOLUTE)


Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)



E7449 also known as 2X-121 (8-(isoindolin-2-ylmethyl)-2,9-dihydro- 3H-pyridazino[3,4,5-de]quinazolin-3-one) is an orally bioavailable, brain penetrable, small molecule dual Poly(ADP-ribose) polymerase /Tankyrase inhibitor that is not a substrate for...
Status:
Investigational

Class (Stereo):
CHEMICAL (ABSOLUTE)



Veliparib (ABT-888) is a potent inhibitor of PARP, has good oral bioavailability, can cross the blood-brain barrier, and potentiates temozolomide, platinums, cyclophosphamide, and radiation in syngeneic and xenograft tumor models. AbbVie is developin...
KU0058948 is an inhibitor of Poly(ADP-ribose) polymerase (PARP). In addition KU0058948 was shown to activate extracellular signal-regulated kinase 8 (ERK8). It affects viability of leukemia, pancreatic and endometrial cancer cells.
Phenanthridinone, an isoquinoline derivative, is a potent poly(ADP-ribose)polymerase 1 inhibitor. It could be considered as a potent immunomodulator, and also as the prototype of a new class of adjuncts in cancer chemotherapy.
Status:
US Approved Rx (2024)
First approved in 2018

Class (Stereo):
CHEMICAL (ABSOLUTE)



BMN-673 (8R,9S) is the (8R,9S) enantiomer of BMN-673, known as talazoparib. BMN 673 is a novel inhibitor of nuclear enzyme poly (ADP-ribose) polymerase (PARP) with potential antineoplastic activity.

Showing 1 - 10 of 16 results